

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q79834

Hideaki TADA, et al.

Appln. No.: 10/774,378

Group Art Unit: 1647

Confirmation No.: 1872

Examiner: Robert S LANDSMAN

Filed: February 10, 2004

For: NOVEL POLYPEPTIDES, DNAS ENCODING THE SAME AND USE THEREOF

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:


We enclose a copy of the Official Filing Receipt for the above-identified application and request the following correction(s):

TITLE: OAF065alpha and OAF065beta POLYPEPTIDES

POWER OF ATTORNEY: 65565

Verification for the requested correction(s) is indicated on the Amendment Under 37 CFR § 1.114(c) filed November 5, 2007 with copy of electronic filing receipt.

Respectfully submitted,



Susan J. Mack

Registration No. 30,951

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER

Date: May 19, 2008

STM

NGB



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NUMBER	FILING or 371(c) DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	TOT CLAIMS	IND CLAIMS
10/774,378	02/10/2004	1647	1304	Q79834	20	5

CONFIRMATION NO. 1872

CORRECTED FILING RECEIPT

65565
SUGHRUE-265550
2100 PENNSYLVANIA AVE. NW
WASHINGTON, DC 20037-3213



Date Mailed: 04/14/2008

Receipt is acknowledged of this non-provisional patent application. The application will be taken up for examination in due course. Applicant will be notified as to the results of the examination. Any correspondence concerning the application must include the following identification information: the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. **If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections**

Applicant(s)

Hideaki Tada, Osaka, JAPAN;
Mikio Konishi, Osaka, JAPAN;
Daikichi Fukushima, Osaka, JAPAN;

Assignment For Published Patent Application

ONO PHARMACEUTICAL CO., LTD.

Power of Attorney:

65565

~~John Mion--10879~~ ~~Peter Olexy--24513~~
~~Thomas MacPeak--19292~~ ~~J OSHA--24625~~
~~Robert Seas Jr--21092~~ ~~Louis Gubinsky--24835~~
~~Robert Sloan--22775~~ ~~Neil Siegel--25200~~
~~Darryl Mexic--23063~~ ~~Alan Kasper--25426~~

Domestic Priority data as claimed by applicant

This application is a CON of 09/380,276 08/27/1999 ABN
which is a 371 of PCT/JP98/00799 02/26/1998

Foreign Applications

JAPAN P. HEI. 9-43143 02/27/1997

If Required, Foreign Filing License Granted: 04/12/2004

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US 10/774,378**

Projected Publication Date: Not Applicable

Non-Publication Request: No

Early Publication Request: No

Title

DAFO65alpha and DAFO65 beta POLYPEPTIDES
~~DAFO65A AND DAFO65B POLYPEPTIDES~~

Preliminary Class

530

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

Acknowledgement Receipt

The USPTO has received your submission at **19:22:34** Eastern Time on **05-NOV-2007** by Deposit Account: 194880.

\$ **810** fee paid by e-Filer via *RAM* with Confirmation Number: 3361.

You have also pre-authorized the following payments from your USPTO Deposit Account:

Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

COPY**eFiled Application Information**

EFS ID	2427602
Application Number	10774378
Confirmation Number	1872
Title	OAF065a AND OAF06513 POLYPEPTIDES
First Named Inventor	Hideaki Tada
Customer Number or Correspondence Address	65565
Filed By	Susan Joan Mack/LISA TAYLOR
Attorney Docket Number	Q79834
Filing Date	10-FEB-2004
Receipt Date	05-NOV-2007
Application Type	Utility under 35 USC 111(a)

Application Details

Submitted Files	Page Count	Document Description	File Size	Warnings
Q79834_RCE_TRANSMITTAL.pdf	1	Request for Continued Examination (RCE)	56331 bytes	▲ WARNINGS
This is not a USPTO supplied RCE SB30 form.				
Q79834_AMENDMENT_1_114.pdf	9	Amendment Submitted/Entered with Filing of CPA/RCE	328562 bytes	◆ PASS
Q79834_ENGLISH_TRANS_PRIORITY_DOC.pdf	52	Miscellaneous Incoming Letter	1690666 bytes	◆ PASS
Q79834_IDS.pdf	3	Information Disclosure Statement (IDS) Filed	122557 bytes	▲ WARNINGS
This is not an USPTO supplied IDS fillable form				
fee-info.pdf	2	Fee Worksheet (PTO-06)	8156 bytes	◆ PASS

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53 (b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this

Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.

If you need help:

- *Call the Patent Electronic Business Center at (866) 217-9197 (toll free) or e-mail EBC@uspto.gov for specific questions about Patent e-Filing.*
- *Send general questions about USPTO programs to the [USPTO Contact Center \(UCC\)](#).*
- *If you experience technical difficulties or problems with this application, please report them via e-mail to [Electronic Business Support](#) or call 1 800-786-9199.*

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q79834

Hideaki TADA, et al.

COPY

Appln. No.: 10/774,378

Group Art Unit: 1646

Confirmation No.: 1872

Examiner: Eileen B. O'HARA

Filed: February 10, 2004

For: OAFO6A AND OAF06513 POLYPEPTIDES

AMENDMENT UNDER 37 C.F.R. § 1.114(c)

MAIL STOP RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Notice of Allowance dated August 8, 2007, please amend the above-identified application as follows on the accompanying pages.

TABLE OF CONTENTS

AMENDMENTS TO THE SPECIFICATION	2
AMENDMENTS TO THE CLAIMS	3
REMARKS	4

AMENDMENTS TO THE SPECIFICATION

Please replace the present title with the following amended title:

~~OAF065A~~ OAF065alpha AND ~~OAF06513~~ OAF065beta POLYPEPTIDES

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

11. (previously presented): A substantially purified form of a polypeptide that comprises the amino acid sequence shown in SEQ ID NO: 4 or 8.
20. (original): A polypeptide in substantially purified form having the amino acid sequence of residues 1 to 392 of SEQ ID NO: 4.
21. (original): A polypeptide in substantially purified form having the amino acid sequence of residues 1 to 398 of SEQ ID NO: 8.

REMARKS

Claims 11, 20 and 21 are all the claims pending in the application, and are allowed.

The title of the invention has been amended to correct clerical errors in the characters, as supported, for example, at page 1, line 10 of the specification. The changes are editorial in nature and no question of new matter or questions of further search arise.

Request for Acknowledgment of Priority and Receipt of Priority Document

The present application claims priority to Japanese Application P. Hei. 9-43143, filed February 27, 1997, as shown in the Declaration and Power of Attorney and cover letter that accompanied the filing of the Application, copies of which are attached hereto.

Further, receipt of a certified copy of the Priority Document was acknowledged in parent application no. 09/380,276 at least in the Office Action mailed August 12, 2003.

Accordingly, the Examiner is requested, respectively, to acknowledge in the present application, applicant's claim to priority and receipt of the certified copy of the priority document in parent application no. 09/380,276.

In view of the above, reconsideration and allowance of this application are now believed to be in order, and such actions are hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, the Examiner is kindly requested to contact the undersigned at the telephone number listed below.

AMENDMENT UNDER 37 C.F.R. § 1.114(c)
Application No.: 10/774,378

Attorney Docket No.: Q79834

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.


Respectfully submitted,

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON DC SUGHRUE/265550

65565

CUSTOMER NUMBER


Susan J. Mack
Registration No. 30,951

Date: November 5, 2007